All In Biotech

Drug Trial Radar · NCT06852222

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 4, 2025

Primary completion

Jun 22, 2029

Study completion Aug 15, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • BleximenibDrug

    Bleximenib will be administered orally.

  • Venetoclax (VEN)Drug

    VEN will be administered orally.

  • Azacitidine (AZA)Drug

    AZA will be administered intravenously or subcutaneously.

  • PlaceboDrug

    Placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who Achieve Complete Remission (CR)Time frame: Up to 4 years and 1 month
  2. Overall Survival (OS)Time frame: Up to 4 years and 1 month

Locations

270 sites in 26 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Cancer Treatment Center of America Phoenix

    Goodyear, Arizona · Recruiting

  • The University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • University of Arkansas at Little Rock

    Little Rock, Arkansas · Recruiting

  • City of Hope

    Duarte, California · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Rocky Mountain Cancer Centers

    Aurora, Colorado · Recruiting

  • Medical Oncology Hematology Consultants, PA

    Newark, Delaware · Recruiting

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida · Recruiting

  • Jupiter Research

    Jupiter, Florida · Recruiting

  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando

    Orlando, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Memorial Cancer Institute

    Pembroke Pines, Florida · Recruiting

  • Moffit Cancer center

    Tampa, Florida · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • Illinois Cancer Specialists

    Niles, Illinois · Recruiting

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • UofL Health Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • MaineHealth Institute for Research

    South Portland, Maine · Recruiting

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Trinity Health Michigan Heart - Ann Arbor Campus

    Ypsilanti, Michigan · Recruiting

  • Washington University in St Louis

    St Louis, Missouri · Recruiting

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • New York Presbyterian - Weill Cornell

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Einstein-Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Atrium Health

    Charlotte, North Carolina · Recruiting

  • Novant Health Charlotte

    Charlotte, North Carolina · Recruiting

  • Carolina Oncology Specialists

    Charlotte, North Carolina · Recruiting

  • Novant Health Winston Salem

    Winston-Salem, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center

    Winston-Salem, North Carolina · Recruiting

Showing 40 of 270 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.